Metabolic Impact of Intermittent Fasting in Early Type 2 Diabetes

Exclusion Criteria

• •Current diabetes treatment with insulin, glucagon-like peptide-1 receptor agonists, sodium-glucose co-transporter 2 (SGLT-2) and/or sulfonylureas
• •Involvements in any other clinical study on lifestyle intervention or requiring drug therapy
• •Any history or eating disorder
• •Renal dysfunction as evidenced by estimated glomerular filtration rate \<45 mL/min by Modification of Diet in Renal Disease (MDRD) formula
• •Hepatic disease considered to be clinically significant (includes jaundice, chronic hepatitis, or previous liver transplant) or transaminases \>2.5x the upper limit of normal
• •Malignant neoplasm requiring chemotherapy, surgery, radiation or palliative therapy within the previous 5 years (with the exception of basal cell skin cancer)
• •Any other factor likely to limit adherence to the study, in the opinion of the investigators